These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 22357972

  • 1. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor.
    Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE.
    J Pharmacol Exp Ther; 2012 May; 341(2):518-31. PubMed ID: 22357972
    [Abstract] [Full Text] [Related]

  • 2. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE.
    Biochemistry; 2004 Apr 06; 43(13):3996-4011. PubMed ID: 15049707
    [Abstract] [Full Text] [Related]

  • 3. Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism.
    Sullivan SK, Hoare SR, Fleck BA, Zhu YF, Heise CE, Struthers RS, Crowe PD.
    Biochem Pharmacol; 2006 Sep 28; 72(7):838-49. PubMed ID: 16930559
    [Abstract] [Full Text] [Related]

  • 4. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
    Gordon JC, Edwards P, Elmore CS, Lazor LA, Paschetto K, Bostwick R, Sylvester M, Mauger R, Scott C, Aharony D.
    Eur J Pharmacol; 2010 Dec 15; 649(1-3):59-63. PubMed ID: 20854803
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors.
    Zhang G, Huang N, Li YW, Qi X, Marshall AP, Yan XX, Hill G, Rominger C, Prakash SR, Bakthavatchalam R, Rominger DH, Gilligan PJ, Zaczek R.
    J Pharmacol Exp Ther; 2003 Apr 15; 305(1):57-69. PubMed ID: 12649353
    [Abstract] [Full Text] [Related]

  • 6. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE.
    Peptides; 2005 Mar 15; 26(3):457-70. PubMed ID: 15652653
    [Abstract] [Full Text] [Related]

  • 7. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G.
    J Pharmacol Exp Ther; 2001 Jan 15; 296(1):113-20. PubMed ID: 11123370
    [Abstract] [Full Text] [Related]

  • 8. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
    Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW.
    J Pharmacol Exp Ther; 1999 Feb 15; 288(2):729-34. PubMed ID: 9918582
    [Abstract] [Full Text] [Related]

  • 9. Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor.
    Hoare SR, Brown BT, Santos MA, Malany S, Betz SF, Grigoriadis DE.
    Biochem Pharmacol; 2006 Jul 14; 72(2):244-55. PubMed ID: 16750175
    [Abstract] [Full Text] [Related]

  • 10. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T, Obitsu T, Minamoto C, Sugiura T, Matsumura N, Ueno S, Kishi A, Katsumata S, Nakai H, Toda M.
    Bioorg Med Chem; 2011 Oct 15; 19(20):5955-66. PubMed ID: 21930387
    [Abstract] [Full Text] [Related]

  • 11. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR, Fleck BA, Gross RS, Crowe PD, Williams JP, Grigoriadis DE.
    Mol Pharmacol; 2008 May 15; 73(5):1371-80. PubMed ID: 18239030
    [Abstract] [Full Text] [Related]

  • 12. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C, Wilcoxen KM, Huang CQ, Xie YF, McCarthy JR, Webb TR, Zhu YF, Saunders J, Liu XJ, Chen TK, Bozigian H, Grigoriadis DE.
    J Med Chem; 2004 Sep 09; 47(19):4787-98. PubMed ID: 15341493
    [Abstract] [Full Text] [Related]

  • 13. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y, Liao Q, Wei J, Gao Q.
    Neurochem Int; 2010 Jan 09; 56(1):107-17. PubMed ID: 19782115
    [Abstract] [Full Text] [Related]

  • 14. Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modeling.
    Dzierba CD, Tebben AJ, Wilde RG, Takvorian AG, Rafalski M, Kasireddy-Polam P, Klaczkiewicz JD, Pechulis AD, Davis AL, Sweet MP, Woo AM, Yang Z, Ebeltoft SM, Molski TF, Zhang G, Zaczek RC, Trainor GL, Combs AP, Gilligan PJ.
    J Med Chem; 2007 May 03; 50(9):2269-72. PubMed ID: 17402721
    [Abstract] [Full Text] [Related]

  • 15. Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor.
    Heise CE, Sullivan SK, Crowe PD.
    J Biomol Screen; 2007 Mar 03; 12(2):235-9. PubMed ID: 17208923
    [Abstract] [Full Text] [Related]

  • 16. Kinetic and equilibrium studies of Ah receptor-ligand binding: use of [125I]2-iodo-7,8-dibromodibenzo-p-dioxin.
    Bradfield CA, Kende AS, Poland A.
    Mol Pharmacol; 1988 Aug 03; 34(2):229-37. PubMed ID: 2842655
    [Abstract] [Full Text] [Related]

  • 17. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB.
    Mol Pharmacol; 1996 Sep 03; 50(3):679-86. PubMed ID: 8794910
    [Abstract] [Full Text] [Related]

  • 18. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
    Li YW, Hill G, Wong H, Kelly N, Ward K, Pierdomenico M, Ren S, Gilligan P, Grossman S, Trainor G, Taub R, McElroy J, Zazcek R.
    J Pharmacol Exp Ther; 2003 Apr 03; 305(1):86-96. PubMed ID: 12649356
    [Abstract] [Full Text] [Related]

  • 19. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.
    Yamada Y, Mizutani K, Mizusawa Y, Hantani Y, Tanaka M, Tanaka Y, Tomimoto M, Sugawara M, Imai N, Yamada H, Okajima N, Haruta J.
    J Med Chem; 2004 Feb 26; 47(5):1075-8. PubMed ID: 14971886
    [Abstract] [Full Text] [Related]

  • 20. 2-Arylpyrimidines: novel CRF-1 receptor antagonists.
    Yoon T, De Lombaert S, Brodbeck R, Gulianello M, Krause JE, Hutchison A, Horvath RF, Ge P, Kehne J, Hoffman D, Chandrasekhar J, Doller D, Hodgetts KJ.
    Bioorg Med Chem Lett; 2008 Aug 15; 18(16):4486-90. PubMed ID: 18672365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.